Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.

ABSTRACT:

Purpose

A subset of patients with myelodysplastic syndromes (MDS) who are predicted to have lower-risk disease as defined by the International Prognostic Scoring System (IPSS) demonstrate more aggressive disease and shorter overall survival than expected. The identification of patients with greater-than-predicted prognostic risk could influence the selection of therapy and improve the care of patients with lower-risk MDS.

Patients and methods

We performed an independent validation of the MD Anderson Lower-Risk Prognostic Scoring System (LR-PSS) in a cohort of 288 patients with low- or intermediate-1 IPSS risk MDS and examined bone marrow samples from these patients for mutations in 22 genes, including SF3B1, SRSF2, U2AF1, and DNMT3A.

Results

The LR-PSS successfully st

SUBMITTER: Bejar R 

PROVIDER: S-EPMC3438234 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature